Deciphering the miRNA-mRNA Interaction Landscape between Breast Cancer and Triple-Negative Breast Cancer: An

Ambritha Balasundaram1, Tanisha Saurav Mitra1, Iftikhar Aslam Tayubi2

  • 1Laboratory of Integrative Genomics, Department of Integrative Biology, School of BioSciences and Technology, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India.

ACS Omega
|June 17, 2024
PubMed

Insights

This study identifies key microRNAs (miRNAs) and messenger RNAs (mRNAs) involved in breast cancer (BC) and triple-negative breast cancer (TNBC). Downregulated miRNAs like hsa-miR-548a-3p show potential as prognostic indicators for BC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background:

  • Breast cancer (BC) is a leading global cancer, with subtypes like triple-negative breast cancer (TNBC) lacking specific therapeutic targets.
  • Identifying novel regulatory molecules, such as microRNAs (miRNAs), is crucial for developing targeted therapies for aggressive BC subtypes.
  • Current BC classification relies on receptor status (HER2, ER, PR), necessitating further molecular stratification.

Purpose of the Study:

  • To identify common differentially expressed messenger RNAs (DE-mRNAs) in breast cancer (BC), including triple-negative breast cancer (TNBC).
  • To predict and validate microRNAs (miRNAs) that target these DE-mRNAs, focusing on their role in BC and TNBC.
  • To explore the potential of identified miRNAs and mRNAs as therapeutic targets and prognostic biomarkers for BC.

Main Methods:

  • Utilized publicly available datasets (GEO, TCGA) to identify 159 common DE-mRNAs across BC and TNBC.
  • Employed network analysis tools (Cytoscape plugins) to pinpoint the top 10 significant DE-mRNAs.
  • Predicted target miRNAs using mirDIP and validated key miRNA-mRNA interactions in TNBC datasets.

Main Results:

  • Identified significant miRNA-mRNA interactions, including hsa-miR-802/MELK, hsa-miR-1258/NCAPG, miR-548a-3p/CCNA2, and hsa-miR-2053/NUSAP1, in both BC and TNBC.
  • Discovered four downregulated DE-miRNAs (hsa-miR-802, hsa-miR-1258, hsa-miR-548a-3p, hsa-miR-2053) significantly associated with TNBC.
  • Found that downregulation of hsa-miR-548a-3p correlates with reduced BC patient survival, while altered expression of mRNAs like CCNB2, UBE2C, MELK, and KIF2C is linked to poorer outcomes.

Conclusions:

  • Specific miRNA-mRNA interactions represent crucial regulatory mechanisms in BC and TNBC.
  • Downregulated hsa-miR-548a-3p serves as a potential prognostic indicator for breast cancer.
  • Aberrantly expressed mRNAs (CCNB2, UBE2C, MELK, KIF2C) are promising therapeutic targets for both BC and TNBC.